von Willebrand factor (vWF) is a large, multimeric glycoprotein that helps platelets adhere to vascular subendothelium. Although vWF binding to platelet receptors and connective tissue constit-
Introduction
The von Willebrand factor (vWF)' is a heterogeneous multimeric plasma protein that facilitates adhesion of platelets to injured 1. Abbreviations used in this paper: GpIb, glycoprotein Ib vessel wall (1) (2) (3) . Although the mechanism by which vWF promotes adhesion has not been fully delineated, there is evidence that vWF links platelets to the vessel wall by binding to platelet glycoprotein Ib (GpIb), as well as to exposed subendothelial collagen (4) (5) (6) (7) (8) (9) . In previous studies, we, and others, have demonstrated vWF binding to GpIb and competition for binding by a soluble proteolytic fragment of GpIb, glycocalicin (10, 1 1). In addition, there are several reports of vWF binding to fibrillar collagen (7-9, [12] [13] [14] , and we have recently reported the binding and Factor XIII-dependent cross-linking of vWF to monomeric collagen (Bockenstedt, P., and R. I. Handin, manuscript submitted for publication).
There is evidence that vWF has distinct domains that bind either to platelet surface glycoproteins or components of connective tissue (15) (16) (17) (18) (19) . Using a series of monoclonal antibodies directed against specific epitopes on vWF, two groups (15, 16) have demonstrated selective inhibition of vWF binding to collagen or to platelet receptors on GpIb and GpIIb-IIIa. In addition, Girma et al. (18) have used limited proteolysis of vWF polymer to produce fragments with selective binding to either GpIb or the Ilb/Illa complex. The current studies were undertaken to further localize the binding sites on vWF for collagen and GpIb and to develop methods to isolate fragments of vWF polymer containing these functional domains.
Methods
Materials. lodobeads were obtained from Pierce Chemical Co., Rockfield, IL. '251-Na was obtained from New England Nuclear, Boston, MA. Sephacryl S 1000 and Sepharose CL6b were obtained from Pharmacia Fine Chemicals, Piscataway, NJ. Affigel Gelatin Sepharose, high molecular weight standards, and sodium dodecyl sulfate were obtained from Bio-Rad Laboratories, Richmond, CA. Heparin Sepharose (0.92 mg heparin per ml hydrated gel) and dextran sulfate Sepharose (0.62 mg dextran sulfate, Mr 500,000 per ml hydrated gel) were obtained from Bethesda Research Laboratories, Gaithersburg, MD. Ristocetin was obtained from Bio/Data Corp., Hatboro, PA. Bovine serum albumin, polyethylene glycol M, 8 ,000 and M, 20,000, beta-mercaptoethanol, dextran sulfate M, 500,000, aprotinin, and phenylmethylsulfonyl fluoride (PMSF), were obtained from Sigma Chemical Co., St. Louis, MO. Staphylococcal V8 protease was obtained from Miles Laboratories, Inc., Naperville, IL. Human fibronectin was a generous gift from Dr. Jan
McDonagh, Beth Israel Hospital, Boston, MA. All other chemicals were reagent grade or better.
Formalin-fixed platelets. These were prepared as previously described (20) and resuspended in 50 mM Tris, 0.15 M NaCl, 0.02% sodium azide, pH 7.4 at a final concentration of 6 X 105 platelets per microliter. The ability of native vWF polymers to agglutinate formalin-fixed platelets was determined in the presence of 1 mg/ml ristocetin (21, 22) and agglutination was monitored on a Payton dual-channel aggregometer (Payton Scientific, Inc., Buffalo, NY). Sodium dodecyl sulfate polyacryl-vWF purification. vWF was purified by a modification of the procedure of Kao et al. (4) . 5 liters of plasma obtained within 2-3 d of collection from the American Red Cross Blood Services-Northeast Region (Boston, MA), frozen at -20'C for 24 h, and thawed at 4VC for 18 h was used as the starting material. The resulting cryoprecipitate was collected by centrifugation at 6,500 g for 20 min, resuspended in 20 mM Na citrate, pH 6.1, and reprecipitated twice with final concentrations of 5 and 12% polyethylene glycol (M, 8 ,000) (PEG) as previously described.
The final precipitate was collected by centrifugation at 6,500 g for 30 min, the pellet surface was washed twice with ice-cold 0.02 M Tris, 0.15 M NaCI, 8% ethanol, pH 7.4 to remove residual PEG, and was resuspended in 10-15 ml of 0.05 M Tris, 0.15 M NaCl, 0.02% azide, pH 7.4 (TBS), and applied to a 2.5 X 90 cm siliconized glass column containing Sephacryl S 1000. 4-ml fractions, collected at a 70 ml/h flow rate, were analyzed for ristocetin-dependent platelet agglutinating activity (21) , protein concentration by the method of Lowry (24) , and for purity by 5% SDS-PAGE after disulfide bond reduction, as described above (23) . Those fractions demonstrating a single 220,000-D band on 5% SDS-PAGE were pooled and concentrated by precipitation with 35% (wt/vol) ammonium sulfate followed by centrifugation at 34,800 g for 30 min at 4VC. The precipitate was then resuspended in a small volume of TBS and dialyzed extensively against TBS. Purified vWF was then stored at -20'C in 250-Al aliquots for up to 3 wk.
Iodination ofvWF. vWF was iodinated using the iodobead technique. One iodobead was preincubated with 0.5-1.0 mCi '25I-Na and 100 y1 of TBS for 10 min at room temperature, followed by addition of 500 ,ug of purified vWF. After 10 min, the iodination was stopped by transfer of the vWF solution to aO.7 X 10cm Sephadex G-25 column preequilibrated with a 1 mg/ml bovine serum albumin solution in TBS and eluted with TBS. Typical specific radioactivity of vWF was 0.20-0.25 gCi/Ag protein.
Preparation ofreduced-alkylated vWF. 3 mg of purified native vWF was incubated with 10 mM beta-mercaptoethanol at room temperature for 3 h and then carboxymethylated with 40 mM iodoacetamide for 20 min. The reduced, alkylated vWF was then gel-filtered on a 1 cm X 92 cm Sepharose CL6b column in 50 mM Tris, 0.5 M NaCI, 0.02% sodium azide, pH 7.4. i-ml fractions were collected and the absorbance at 280 nm was measured. The vWF oligomer produced by reduction and alkylation typically eluted at fractions 55-65. The desired fractions were pooled and concentrated by dialysis against 20% polyethylene glycol M, 20 ,000 in TBS. Samples of the vWF oligomer were analyzed under reducing and nonreducing conditions on 4.3% SDS-PAGE.
Affinity chromatography. Studies of vWF binding to dextran sulfate (Mr 500,000) and heparin substituted Sepharose columns were performed at room temperature on 0.9 X 6 cm siliconized glass columns containing 6 ml of gel. The columns were equilibrated with 0.05 M Tris, 0.15 M NaCl, pH 7.4 containing 0.1% bovine serum albumin (wash buffer). 10 ;g of '25I-vWF in 0.5 ml ofthe same buffer were applied to each column and 2 ml ofbuffer eluted to distribute the sample throughout the column volume. 1 h later, the column was washed with 50 ml ofthe same buffer at a flow rate of 10 ml/h. The effluent, collected in 2.5 ml fractions, was monitored for radioactivity. Once background levels of radioactivity were achieved, a 50-ml linear gradient of 0.15-1.5 M NaCl in 0.05 M Tris, pH 7.4 containing 0.1% albumin was applied at a flow rate of 20 ml/h. The effluent, collected in 2.5 ml fractions, was again monitored for radioactivity.
In some experiments, the heparin sepharose column eluates were analyzed on 5% SDS-PAGE. In analysis on 8.75% SDS-PAGE under reducing conditions. After 4 h, 10 U/ml aprotinin and 5 mM PMSF were added, and the protein digest was applied to a 5 ml heparin Sepharose column and allowed to equilibrate for 30-60 min at room temperature. The unbound protein fragments were then eluted with 25 ml of 50 mM Tris, 0.15 M NaCl 0.02% azide, pH 7.4 at a flow rate of 10 ml/h. Protein fragments bound to heparin Sepharose were eluted with 30 ml of 50 mM Tris, 1.0 M NaCl, pH 7.4 at a flow rate of 10 ml/h. The l.0-M and 0.15-M NaCl eluates were then individually dialyzed against distilled water, frozen in a dry ice acetone bath, lyophilized, and stored at -20'C until further use. Lyophilized samples were resuspended in TBS containing 10 U/ml aprotinin and 5 mM PMSF. Platelet binding assay. Varying concentrations of native vWF polymer, reduced, alkylated vWF oligomer, or proteolytic fragments were added to assays containing 1 Ag/ml '25I-vWF polymer or reduced, alkylated oligomer, 50 ,l of formalin-fixed platelets (600,000 platelets/gl), and sufficient TBS to bring the final volume to 200 td. Incubations were initiated by the addition of 0.5 mg/ml ristocetin with stirring. After 60 min, 100 td of each assay was layered on 200 tdI 30% sucrose cushions in 400 !d conical polypropylene tubes and platelet-bound 1251-vWF was separated from free by centrifugation at 10,000 g for 4 min at 4°C. The supernatant was aspirated, the tips containing platelet pellets sliced off, and total radioactivity determined in a Beckman gamma spectrometer (Beckman Instruments, Inc.).
Collagen binding assay. 100 ,l of acid-soluble calfskin collagen in 20 mM Na citrate, pH 6.1 (1.8 mg/ml) were incubated in individual microtiter wells for 90 min at room temperature. Residual unbound collagen was removed by aspiration and the wells were washed three times with TBS. The wells were then filled completely with a 2 mg/ml albumin solution in TBS and incubated for 1 h at room temperature (15) . The wells were then decanted and were ready for immediate use in collagen binding assays. 1 Ug/ml '251-vWF, varying concentrations (0-700 ,ug/ml) ofvWF polymer, dimer, or vWF digest fragment to be tested, and sufficient TBS to bring the final assay volume to 100 gl were added to the collagen-coated microtiter wells. After 1 h at room temperdture, the wells were aspirated dry, washed three times with TBS, and bound radioactivity was measured in a gamma spectrometer.
Results
Previous studies of vWF binding to the piatelet have utilized heterogeneous fractions of polymeric vWF as radioligands (25) (26) (27) (28) . Binding ofthese vWF fractions to GpIb requires the addition of the cationic antibiotic, ristocetin (4). In addition, binding is saturable and reversible with virtually all the polymeric 1251_ vWF bound to the platelet in the presence of ristocetin readily displaced by nonradiolabeled vWF polymer (4, 25, 26) . We have recently shown that vWF polymers also bind to collagen monolayers in a saturable, reversible, and specific fashion (Bockenstedt, P., and R. I. Handin, manuscript submitted for publication). In the current studies, an oligomer of vWF was produced from vWF polymer by limited disulfide reduction and alkylation. As shown in Fig. 1 (inset, lane 1 Fig. 2 B, vWF and vWFd were competed against '251I-vWFd. In this experiment, the IC50 for polymer and dimer was 4±0.5 gg/ml (-4.2 nM) and 19±2 ,g/ml (47 nM), respectively, assuming an average Mr of 1.2 X 106 for polymeric vWF.
In contrast to the results obtained with the platelet, vWFd does not compete with '251-vWF polymer for binding to collagen monolayers (Fig. 3) . This suggests that the domain on vWF responsible for binding to collagen is unfavorably altered during the reduction and alkylation procedure used to produce vWFd or that collagen binding requires a higher order oligomer.
Previous studies from our laboratory have demonstrated that vWFd can reassociate into larger oligomers when incubated at the concentrations used in our assay (29) . Thus, the effective free concentration of vWF dimer available for binding to the platelet may be reduced by the formation ofnoncovalently linked oligomers. This creates a complex set of equilibria with both dimer-dimer and dimer-GpIb interactions. To eliminate the possibility that vWFd reassociate during the binding studies, and to further localize the regions on vWF that bind to GpIb and collagen, proteolytic fragments of vWF were produced by incubation of vWF polymer with Staphylococcal V8 protease. As shown in Fig. 4 (Fig. 4) .
To determine whether any of these proteolytic products retained functional activity, we tested fragments 1 and 2 for their ability to compete with native '251-vWF for binding to platelet GpIb and collagen monolayers. As shown in Fig. 6 A, fragment 1, which was not retained by heparin Sepharose, did not compete with '25I-vWF polymer for binding to Gplb. Fragment 2, however, which had an estimated Mr of 285,000 and was retained on heparin Sepharose, competed with native '25I-vWF for binding to GpIb with an IC5o of 22±3 Ag/ml (77 nM). Neither of these fragments competed with '25I-vWF polymer for binding to collagen monolayers (Fig. 6 B) . These studies suggest that the domains on vWF that bind to GpIb and heparin are located on a 285,000-D proteolytic fragment derived from polymeric vWF, while binding to collagen, which is lost by thiol reduction or proteolysis, requires the more complex quaternary structure present in vWF polymer.
Discussion
Although vWF is multifunctional and binds to platelet GpIb (5, 6, 25, 26) , GpIIb-IIIa (30) (31) (32) , components of the subendothelium such as collagen (7) (8) (9) 16 ) and Factor VIII:C (28, 33) , the domain on native vWF polymer that binds to each of these receptors or proteins has not been localized. One our studies indicate (Fig. 1) , reduction and alkylation is seldom complete, and a small amount of high molecular weight polymer may remain unless a purification scheme is designed to specifically remove these polymers. We have shown here that a vWF dimer, produced by reduction and alkylation, binds to platelet GpIb. In addition, when this dimeric form was used as a radioligand, both unlabeled dimer and polymer competed for binding. These data suggest that the binding domain for GpIb is retained in a 440,000-mol-wt subunit of polymeric vWF. The disparity in IC5o between native polymer and dimer may reflect cooperativity in binding between multiple disulfide-linked subunits in the native polymer leading to multiple platelet interactions for each vWF polymer or, alternatively, may reflect noncovalent self-association between the reduced, alkylated subunit dimers to form aberrant vWF polymers with only a limited number of platelet binding sites.
Sixma et al. (38) have shown that a reduced, alkylated form of vWF can bind to the subendothelium and enhance platelet adhesion at low but not high shear rates. In contrast, we were unable to show that our vWFd species binds to collagen coated microtiter wells. This may be due to steric interference with the 4 .3% SDS-PAGE analysis of vWF proteolytic fragments isolated by chromatography on heparin Sepharose. 3 mg of vWF polymer were digested with 10 Atg Staphylococcal V8 protease for 4 h at 370C as previously described and applied to a 5 ml heparin Sepharose column. A portion of the vWF appeared in the wash through volume (fiagment 1). Bound vWF fiagments were then eluted with 1 M NaCl (fragment 2). Fragments I and 2 were dialyzed against distilled H20, Iyophilized, and resuspended in 1 ml TBS containing 10 U/ml aprotinin and 5 Although we have used heparin as a convenient tool for isolation of proteolytic fragments of vWF, the observed affinity ofvWF polymer for heparin may merit additional investigation. The ability of vWF to bind to heparin has been previously noted, but incompletely defined (40, 41) . Two other adhesive proteins present in extracellular matrix, fibronectin and laminin, also share similar affinities for heparin and dextran sulfate sepharose (41) (42) (43) (44) (45) . The binding of heparin to fibronectin enhances the binding of fibronectin to collagen (43, 44) . Laminin also has binding sites for tissue glycosaminoglycans as well as type IV collagen (45) . In similar fashion, this specific, high affinity interaction of vWF with glycosaminoglycans may explain one of the mechanisms by which vWF becomes bound to the subendothelium. It is conceivable that the binding of vWF to heparinlike molecules within the subendothelium may actually facilitate interaction of vWF domains with platelet surface receptors or, conversely, the binding of vWF to the platelet receptor may facilitate the binding to the subendothelium. In addition, tissue glycosaminoglycans have been implicated in the polymerization process of matrix fibronectin (46) and collagen (47) . Thus, heparin-vWF interactions may be important in polymerization of vWF from dimer into oligomers at the endothelial cell surface. Since the species and amount of extracellular matrix glycosaminoglycans can be influenced by cell culture conditions, the interaction ofvWF with certain glycosaminoglycans may explain the discrepancy in vWF polymer size in the medium ofcultured endothelial cells described by several laboratories (48) (49) (50) . Lastly, the affinity of vWF for sulfated glycosaminoglycans like heparin may have no role in vWF-mediated platelet adhesion in vivo. These possibilities will be the subject of our future investigations.
Although platelet agglutinating activity is associated with higher molecular weight forms of vWF, we have shown that binding of vWF to GpIb can be localized to a 440,000-D dimer of native vWF produced by limited disulfide reduction and alkylation and to a smaller 285,000 proteolytic fragment of native vWF. This 285,000-D fragment also has a heparin binding domain. The affinity of vWF for heparin can be used to purify this fragment and separate it from fragments that do not have heparin binding activity and do not bind to GpIb. These studies help to define the structural requirements for vWF binding to GpIb, collagen, and heparin and provide a means to localize these binding domains within vWF polymers.
